Sugi Predict

Sugi Predict / Compounds / SCHEMBL8328277

SCHEMBL8328277

SCHEMBL8328277

N#CCC(O)COCc1ccccc1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CA1 P00915 5/20 0.62
▸ CA2 P00918 3/20 0.62
▸ CA7 P43166 3/20 0.62
▸ CA9 Q16790 3/20 0.62
▸ MAPK1 P28482 1/20 0.50
▸ TSHR P16473 2/20 0.48
▸ POLB P06746 1/20 0.46
▸ PRMT5 O14744 1/20 0.46
▸ WDR77 Q9BQA1 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46
▸ CYP3A4 P08684 1/20 0.46
▸ CYP2D6 P10635 1/20 0.46
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ AGER Q15109 1/20 0.46
▸ CA4 P22748 1/20 0.44
▸ TACR1 P25103 2/20 0.44
▸ KMT2A Q03164 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27686748 1.00 CA1 (0.62) CA1CA2CA7CA9MAPK1
SCHEMBL6580596 1.00 CA1 (0.62) CA1CA2CA7CA9MAPK1
SCHEMBL397022 0.83 CA1 (0.78) CA1CA2CA7CA9MAPK1
SCHEMBL10493999 0.83 CA1 (0.62) CA1CA2CA7CA9MAPK1
SCHEMBL9870444 0.83 CA1 (0.62) CA1CA2CA7CA9MAPK1
SCHEMBL9870455 0.83 CA1 (0.62) CA1CA2CA7CA9MAPK1
SCHEMBL3325707 0.82 TSHR (0.50) CA1CA2CA7CA9MAPK1
SCHEMBL15939041 0.80 CA1 (0.58) CA1CA2CA7CA9MAPK1
SCHEMBL7153591 0.80 CA1 (0.76) CA1CA2CA7CA9MAPK1
SCHEMBL4898269 0.79 TSHR (0.47) CA1CA2CA7CA9TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101130538-A Method for preparing (4R-Cis)-6-methylol-2, 2-dimethyl-1,3-dioxane-4-tert-butyl acetate UNIV ZHEJIANG (CN) 2008-02-27 — — CN claimed
EP-0789571-A4 CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO INC (US) 1999-04-14 — — EP claimed
EP-0789571-A1 CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE Merck & Co., Inc. (US) 1997-08-20 — — EP claimed
WO-1996014844-A1 CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO., INC. (US) 1996-05-23 — — WO claimed
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof NEWAVE PHARMACEUTICAL INC. (US) 2026-03-10 — — US disclosed
US-20250073340-A1 SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF NEWAVE PHARMACEUTICAL INC. 2025-03-06 — — US disclosed
US-20230399319-A1 Acylsulfamide Compound and Pharmaceutical Use Therefor JAPAN TOBACCO INC. (JP) 2023-12-14 — — US disclosed
US-20230399319-A1 Acylsulfamide Compound and Pharmaceutical Use Therefor JAPAN TOBACCO INC. (JP) 2023-12-14 — — US disclosed
US-20230399319-A1 Acylsulfamide Compound and Pharmaceutical Use Therefor JAPAN TOBACCO INC. (JP) 2023-12-14 — — US disclosed
EP-4082614-A1 ACYLSULFAMIDE COMPOUND AND PHARMACEUTICAL USE THEREFOR Japan Tobacco Inc. (JP) 2022-11-02 — — EP disclosed
CN-114829345-A Acylsulfonamide compound and medicinal use thereof 日本烟草产业株式会社 2022-07-29 — — CN disclosed
WO-2022159644-A1 SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF NEWAVE PHARMACEUTICAL INC. (US) 2022-07-28 — — WO disclosed
CN-101130538-A Method for preparing (4R-Cis)-6-methylol-2, 2-dimethyl-1,3-dioxane-4-tert-butyl acetate UNIV ZHEJIANG (CN) 2008-02-27 — — CN disclosed
CN-1932031-A Enzyme resolving process for preparing chiral beta-hydroxy nitrile UNIV ZHEJIANG (CN) 2007-03-21 — — CN disclosed
CN-1923792-A (S) 6-arylmethyl-5-hydroxyl-3-oxy-hecanoic acid t-butyl ester and preparation method thereof UNIV ZHEJIANG (CN) 2007-03-07 — — CN disclosed
EP-0760368-B1 PYRIMIDINE DERIVATIVES NISSHIN FLOUR MILLING CO (JP) 1999-07-28 — — EP disclosed
US-5736550-A TREATMENT OF GASTROINTESTINAL TRACT DISORDERS NISSHIN FLOUR MILLING CO., LTD. (JP) 1998-04-07 — — US disclosed
US-5629322-A TREATMENT OF NEURODEGENERATIVE DISORDERS, DISORDERS OF GASTROINTESTINAL MOTILITY AND INFLAMMATION MERCK & CO., INC. (US) 1997-05-13 — — US disclosed
EP-0760368-A1 NOVEL PYRIMIDINE DERIVATIVE NISSHIN FLOUR MILLING CO., LTD. (JP) 1997-03-05 — — EP disclosed
WO-1996014844-A1 CYCLIC AMIDINE ANALOGS AS INHIBITORS OF NITRIC OXIDE SYNTHASE MERCK & CO., INC. (US) 1996-05-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250073340-A1 SPIROCYCLIC MDM2 MODULATOR AND USES THEREOF FOXM1, MDM2, FOXO1 CA1 3248/4885CA2 4514/4885CA7 4569/4885
US-12569564-B2 Spirocyclic MDM2 modulator and uses thereof MDM2, TP53, XIAP CA1 715/4885CA2 2406/4885CA7 1531/4885
US-20230399319-A1 Acylsulfamide Compound and Pharmaceutical Use Therefor NLRP3, NLRP1, NOD1 CA1 3738/4885CA2 1609/4885CA7 1637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.